Most cancerous thyroid nodules grow slowly, with the majority of papillary thyroid cancers (the most common type) doubling in volume roughly every 2.2 years. But growth speed varies dramatically by cancer type, from nodules that barely change over several years to aggressive forms that expand visibly within weeks. Understanding these differences can help you make sense of monitoring timelines and what your doctor is watching for.
Growth Rates by Thyroid Cancer Type
Thyroid cancer isn’t one disease. The type of cancer determines how fast a nodule grows, and the range is enormous.
Papillary thyroid cancer accounts for about 80% of thyroid cancers and is the slowest growing. In a study of 291 patients on active surveillance, only 3.8% saw their tumor grow by 3 mm or more in diameter, and those that did took an average of about 34 months to reach that threshold. The median volume doubling time was 2.2 years, with some tumors taking nearly 5 years to double. Many papillary cancers remain stable for years without any measurable change.
Medullary thyroid cancer grows somewhat faster. The average volume doubling time for metastatic medullary thyroid cancer is about 1.6 years. Growth tends to be constant over time regardless of where the tumor is located. Patients whose tumors double in under a year have significantly worse outcomes, while those with doubling times over 3 years have an excellent prognosis.
Anaplastic thyroid cancer is rare but extremely aggressive. It presents as a rapidly expanding neck mass that can grow noticeably over days to weeks. Most patients die within 6 months of diagnosis due to how quickly it invades surrounding tissue. Survival times range from a few weeks to a few years depending on how advanced the disease is at diagnosis, but the mortality rate approaches 100%.
How Cancerous Growth Compares to Benign Nodules
Growth alone doesn’t confirm cancer, but cancerous nodules do grow faster on average. A study comparing 126 malignant nodules with 1,363 benign ones found that cancerous nodules were 2.5 times more likely to grow faster than 2 mm per year. About 26% of malignant nodules exceeded that pace, compared to only 12% of benign ones. Benign nodules typically grow at roughly 1 mm per year, and nearly 88% of them remained stable or shrank during follow-up.
That said, the overlap is significant. About 74% of cancerous nodules also appeared stable over the monitoring period, growing less than 2 mm per year. So a nodule that isn’t growing quickly could still be malignant, and one that is growing doesn’t necessarily mean cancer. Growth rate is one piece of the puzzle, not a diagnosis on its own.
What Counts as “Significant” Growth
The American Thyroid Association defines significant growth as a 20% increase in at least two dimensions with a minimum increase of 2 mm, or a greater than 50% change in volume. Anything within a 2 mm range in either direction is generally considered stable, since that falls within the normal margin of measurement error between ultrasound readings.
Doctors are increasingly moving toward tracking volume rather than just diameter. A nodule can increase meaningfully in volume before the change shows up in a simple width measurement. Volume-based tracking catches significant growth earlier and produces fewer false alarms. This is the same approach that improved lung cancer screening accuracy, and it’s becoming more common in thyroid monitoring as well.
Factors That Influence Growth Speed
TSH, the hormone that stimulates the thyroid, plays a role. Patients with malignant nodules tend to have higher TSH levels than those with benign ones (1.94 vs. 1.62 on average in one study). Higher TSH makes a nodule about 1.5 times more likely to be cancerous. This is also why some patients with well-differentiated thyroid cancer are placed on thyroid hormone therapy to suppress TSH, which slows disease progression and reduces recurrence.
Age and sex matter too, though their influence is on outcomes more than raw growth speed. Women under 55 have a significantly lower risk of dying from papillary thyroid cancer than men of the same age, likely due to the protective effects of estrogen. After 55, that advantage disappears, and outcomes for men and women become similar. Older age at diagnosis is generally associated with more aggressive disease behavior regardless of sex.
What Happens During Active Surveillance
For small, low-risk papillary thyroid cancers, many doctors now offer active surveillance instead of immediate surgery. This means regular ultrasound monitoring to track whether the nodule changes. The data on this approach is reassuring for most patients.
In a study of 483 patients on active surveillance, only about 16% showed any increase in tumor volume over 5 years. At last follow-up, 82% were still being monitored without any intervention, while just 9.3% had transitioned to surgery. Even among nodules that did grow, an increase in volume wasn’t always treated as an automatic trigger for surgery. Growth patterns vary, and some nodules grow for a period before stabilizing again.
Surveillance typically involves ultrasound every 6 to 12 months in the first few years, with intervals potentially stretching out if the nodule remains stable. The key measurements your doctor tracks are changes in diameter across multiple dimensions and overall volume, compared against the thresholds described above.